ARTICLE | Financial News

Chimerix planning $105M follow-on

October 30, 2014 2:26 AM UTC

Chimerix Inc. (NASDAQ:CMRX) said it plans to raise about $105 million in a follow-on underwritten by Morgan Stanley; JP Morgan; Cowen; Piper Jaffray; and Stifel, Nicolaus.

Chimerix's brincidofovir is in Phase III trials to prevent cytomegalovirus (CMV) infection in adults undergoing hematopoietic stem cell transplant (HSCT). It also is in Phase III testing to treat adenovirus infection and Phase II testing to treat Ebola virus infection. ...